Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma

(Cell 179, 561–577.e1–e22; October 3, 2019) It has come to our attention that a recent and important reference concerning proteomic analysis of hepatocellular carcinoma was inadvertently omitted during the preparation of our paper. The missing reference is: “Jiang, Y., Sun, A., Zhao, Y., Ying, W, Sun, H, Yang, X, Xing, B., Sun, W., Ren, L., Hu, B., et al. (2019). Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature, 567, 257–261.” In the corrected version of this article, this key citation is now referenced in the Introduction. Additionally, an institutional affiliation of our paper was mis-typed during the submission of final manuscript. It should be “4State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.” We apologize for any confusion and inconvenience that these errors may have caused. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular CarcinomaGao et al.CellOctober 03, 2019In BriefProteogenomic characterization of HBV-related hepatocellular carcinoma (HCC) using paired tumor and adjacent liver tissues identifies three subgroups with distinct features in metabolic reprogramming, microenvironment dysregulation, cell proliferation, and potential therapeutics. Full-Text PDF Open Access